61941-90-0

Upstream product

• 54022-99-0 5-(3-trifluoromethylphenyl)furan-2-carboxylic acid 
• 54023-09-5 methyl 5-(3-(trifluoromethyl)phenyl)furan-2-carboxylate 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 585-70-6 5-bromo-furan-2-carboxylic acid 

Downstream Products

• 92973-19-8 {[5-(3-Trifluoromethyl-phenyl)-furan-2-carbonyl]-amino}-acetic acid ethyl ester 
• 92972-98-0 {[1-Chloro-1-[5-(3-trifluoromethyl-phenyl)-furan-2-yl]-meth-(Z)-ylidene]-amino}-acetic acid ethyl ester 
• 92973-09-6 {5-[5-(3-Trifluoromethyl-phenyl)-furan-2-yl]-tetrazol-1-yl}-acetic acid ethyl ester 
• 92972-81-1 {5-[5-(3-Trifluoromethyl-phenyl)-furan-2-yl]-tetrazol-1-yl}-acetic acid 
• 753500-02-6 (1,4-diazabicyclo-[3.2.2]nonan-4-yl)(5-(3-(trifluoromethyl)-phenyl)furan-2-yl)methanone 
• 374633-43-9 (1-benzo[1,3]dioxol-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-[5-(3-trifluoromethyl-phenyl)-furan-2-yl]-methanone 

Relevant academic research and scientific papers

Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation

The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure–activity

Synthesis of heterocycles from arylation products of unsaturated compounds: XVIII. 5-Arylfuran-2-carboxylic acids and their application in the synthesis of 1,2,4-thiadiazole, 1,3,4-oxadiazole, and [1,2,4]triazolo[3,4-b][1,3,4] thiadiazole derivatives

Arylation of furan-2-carboxylic acid or its methyl ester with arenediazonium chlorides in the presence of copper(II) chloride gave the corresponding 5-arylfuran-2-carboxylic acids or methyl 5-arylfuran-2- carboxylates. 5-Arylfuran-2-carbonyl chlorides rea

Furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors for treatment of erectile dysfunction

Synthesis of furoyl and benzofuroyl pyrroloquinolones as potent and selective PDE5 inhibitors was reported. Their in vitro potencies in inhibiting PDE5 and selectivity in inhibiting other PDE isozymes (PDE1-4 and PDE6) were evaluated. Some of these compounds are more potent than sildenafil with better selectivity toward PDE1 and PDE6. Incorporation of solublizing groups resulted in bioavailable analogues. Selected compounds showed in vivo efficacy in anesthetized dog model for penile erection.